Immunotech Biopharm Ltd (HK:6978)
:6978
Want to see HK:6978 full AI Analyst Report?
6978 Stock Chart & Stats
HK$2.68
-HK$0.01(-0.43%)
At close: 4:00 PM EST
HK$2.68
-HK$0.01(-0.43%)
Day’s Range― - ―
52-Week RangeHK$2.30 - HK$5.40
Previous CloseN/A
Volume50.00K
Average Volume (3M)1.34M
Market Cap
HK$1.82B
Enterprise ValueHK$1.78B
Total Cash (Recent Filing)HK$154.63M
Total Debt (Recent Filing)HK$440.26M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding617,500,800
10 Day Avg. Volume1,608,107
30 Day Avg. Volume1,338,788
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)-103.70
Price to Sales (P/S)0.00
P/FCF Ratio-12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sizable Asset BaseA large asset base (603.2M in 2025) provides a structural resource pool to fund R&D, support operations, and collateralize financing. Over the medium term this reduces acute insolvency risk and gives management flexibility to execute development programs or negotiate partnerships.
Material Reduction In DebtSharp decline in reported debt materially eases financial leverage and interest burden, improving structural flexibility. Lower gross debt reduces covenant and refinancing pressure, enhancing the company's ability to prioritize development spending or secure less dilutive funding.
Improving Cash Burn TrajectoryConsistent reduction in operating and free cash outflows shows durable cost containment and operational discipline. A narrowing burn rate extends runway and lowers near-term external funding needs, making the business model progressively less reliant on immediate capital markets.
Bears Say
No Revenue / Pre-commercial StatusAbsence of any recorded revenue across multiple years indicates a pre-commercial biotech profile. This structural lack of operating income forces ongoing dependence on external capital, increasing dilution and execution risk until product commercialization or licensing generates sustainable cash flow.
Negative Equity / Solvency ConcernTransition to negative shareholders' equity is a durable solvency red flag that constrains borrowing capacity and strategic optionality. It raises the probability of covenant breaches, creditor pressure, or dilutive recapitalizations, limiting long-term financial flexibility and investor confidence.
Persistent Operating Losses And Cash BurnChronic annual operating losses and sustained negative cash flows indicate the company is not self-funding and will require continuing external capital. This structural cash burn elevates dilution risk, restricts strategic investments, and poses enduring solvency challenges absent clear revenue or financing solutions.
Immunotech Biopharm Ltd News
6978 FAQ
What was Immunotech Biopharm Ltd’s price range in the past 12 months?
Immunotech Biopharm Ltd lowest stock price was HK$2.30 and its highest was HK$5.40 in the past 12 months.
What is Immunotech Biopharm Ltd’s market cap?
Immunotech Biopharm Ltd’s market cap is HK$1.82B.
When is Immunotech Biopharm Ltd’s upcoming earnings report date?
Immunotech Biopharm Ltd’s upcoming earnings report date is Aug 21, 2026 which is in 115 days.
How were Immunotech Biopharm Ltd’s earnings last quarter?
Immunotech Biopharm Ltd released its earnings results on Mar 20, 2026. The company reported -HK$0.208 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.208.
Is Immunotech Biopharm Ltd overvalued?
According to Wall Street analysts Immunotech Biopharm Ltd’s price is currently Overvalued.
Does Immunotech Biopharm Ltd pay dividends?
Immunotech Biopharm Ltd does not currently pay dividends.
What is Immunotech Biopharm Ltd’s EPS estimate?
Immunotech Biopharm Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunotech Biopharm Ltd have?
Immunotech Biopharm Ltd has 617,500,800 shares outstanding.
What happened to Immunotech Biopharm Ltd’s price movement after its last earnings report?
Immunotech Biopharm Ltd reported an EPS of -HK$0.208 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.959%.
Which hedge fund is a major shareholder of Immunotech Biopharm Ltd?
Currently, no hedge funds are holding shares in HK:6978
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunotech Biopharm Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.94%
12-Months-Change
Fundamentals
Return on Equity
293.08%
Trailing 12-Months
Asset Growth
11.88%
Trailing 12-Months
Company Description
Immunotech Biopharm Ltd
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; and TCR-T cell series products to treat solid tumors. The company was founded in 2006 and is headquartered in Beijing, the People's Republic of China.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
―
SinoMab Bioscience Ltd.
―
Zhaoke Ophthalmology Ltd.
―
Options Prices
Currently, No data available
---